Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-005",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "claude-sonnet-4",
  "action": "support",
  "content": "# Druggability Assessment of Tau Strain-Specific Therapeutic Hypotheses\n\n## 1. Glial Glycocalyx Remodeling Therapy\n\n**Druggability: MODERATE**\n- **HSPG2/EXT1/EXT2**: Limited druggability. EXT1/EXT2 are intracellular enzymes requiring small molecule penetration\n- **Chemical matter**: Heparanase inhibitors exist (SST0001, necuparanib) but are non-selective\n\n**Existing compounds:**\n- **SST0001 (roneparstat)**: Phase II trials for multiple myeloma (NCT02194985)\n- **Necuparanib**: Phase I/II for pancreatic cancer (NCT02921022)\n- **PG545**: Heparanase inhibitor, Phase I completed (NCT02042781)\n\n**Competitive landscape:**\n- Cantex Pharmaceuticals (CX-2029 heparanase inhibitor)\n- Glycomimetics (GlycoEra program)\n\n**Safety concerns:**\n- Heparanase inhibition affects angiogenesis, wound healing\n- Potential bleeding risk due to heparin-like activity\n- Non-selective HSPG effects on growth factor signaling\n\n**Timeline/Cost:**\n- **3-5 years, $15-25M** for repurposing existing compounds\n- **7-10 years, $50-80M** for novel EXT1/EXT2 modulators\n\n## 2. Aquaporin-4 Polarization Rescue\n\n**Druggability: LOW**\n- **AQP4**: Notoriously difficult drug target (water channel)\n- **SNTA1**: Intracellular scaffolding protein, poor druggability\n\n**Existing compounds:**\n- **TGN-020**: AQP4 inhibitor (research tool only)\n- No clinical-stage AQP4 modulators exist\n- No α-syntrophin targeting compounds available\n\n**Competitive landscape:**\n- Virtually non-existent for CNS AQP4 modulation\n- Some activity in peripheral edema (Otsuka, AQP4 research program discontinued)\n\n**Safety concerns:**\n- AQP4 manipulation could worsen brain edema\n- Essential role in water homeostasis\n- Blood-brain barrier integrity issues\n\n**Timeline/Cost:**\n- **8-12 years, $100-150M** for novel AQP4 modulators (high risk)\n- Currently no viable development path\n\n## 3. Microglial Purinergic Reprogramming ⭐ MOST VIABLE\n\n**Druggability: HIGH**\n- **P2Y12**: Well-validated GPCR target\n- **P2RX7**: Established ion channel target with multiple drug programs\n\n**Existing compounds:**\n- **P2Y12 antagonists**: Clopidogrel (Plavix), ticagrelor (Brilinta) - but CNS penetration limited\n- **Brain-penetrant P2Y12**: \n  - **CZC24832** (research tool)\n  - **PSB-0739** (selective P2Y12 antagonist)\n- **P2RX7 antagonists**:\n  - **JNJ-47965567** (Janssen, Phase II for depression, NCT02902601)\n  - **GSK1482160** (GSK, discontinued in Phase I)\n  - **AZD9056** (AstraZeneca, failed RA trials but CNS-active)\n\n**Competitive landscape:**\n- **Janssen**: Active P2RX7 program for psychiatric disorders\n- **Pfizer**: P2RX7 research program\n- **Roche**: Historical P2RX7 development (discontinued)\n- **Evotec**: P2RX7 platform technology\n\n**Safety concerns:**\n- P2Y12 inhibition: bleeding risk (well-characterized from cardiology)\n- P2RX7 antagonism: potential immunosuppression, infection risk\n- Microglial function essential for brain homeostasis\n\n**Timeline/Cost:**\n- **4-6 years, $30-50M** for repurposing existing P2RX7 compounds\n- **6-8 years, $60-100M** for novel brain-penetrant P2Y12 modulators\n\n## 4. Ephrin-B2/EphB4 Axis Manipulation\n\n**Druggability: MODERATE**\n- **EphB4**: Receptor tyrosine kinase, established drug target class\n- **EFNB2**: Cell surface protein, antibody targetable\n\n**Existing compounds:**\n- **EphB4 inhibitors**:\n  - **Dasatinib** (multi-kinase, includes EphB4, FDA-approved for CML)\n  - **NVP-BHG712** (Novartis, Phase I for solid tumors, NCT00788125)\n- **EphB4 agonists**:\n  - **sEphB4-HSA** (Vasgene, Phase I for solid tumors, NCT01642342)\n\n**Competitive landscape:**\n- **VasGene Therapeutics**: EphB4-targeted therapies\n- **HiberCell**: Ephrin receptor modulators\n- Limited CNS-focused activity\n\n**Safety concerns:**\n- Ephrin signaling critical for vascular development\n- Potential effects on angiogenesis and vascular integrity\n- Developmental pathway activation in adults\n\n**Timeline/Cost:**\n- **5-7 years, $40-70M** for repurposing dasatinib or similar\n- **8-10 years, $80-120M** for novel CNS-penetrant EphB4 modulators\n\n## 5. Sphingolipid Metabolism Reprogramming\n\n**Druggability: MODERATE-HIGH**\n- **CERS2/CERS6**: Druggable enzymes with known inhibitors\n- **SMPD1**: Established target with existing modulators\n\n**Existing compounds:**\n- **CERS inhibitors**:\n  - **Fumonisin B1** (mycotoxin, research tool, toxic)\n  - **2-hydroxyoleic acid** (Minerva, Phase II for brain tumors, NCT02759549)\n- **SMPD1 modulators**:\n  - **Amitriptyline** (tricyclic antidepressant, SMPD1 inhibitor)\n  - **Imipramine** (tricyclic, SMPD1 activity)\n  - **ARC39** (acid sphingomyelinase inhibitor, preclinical)\n\n**Competitive landscape:**\n- **Minerva Neurosciences**: 2-hydroxyoleic acid program\n- **Red Hill Biopharma**: Sphingolipid modulators\n- **Apogenix**: Acid sphingomyelinase inhibitors\n\n**Safety concerns:**\n- Sphingolipid metabolism essential for cell membranes\n- Potential effects on myelin and neuronal function\n- Lysosomal storage disease-like phenotypes\n\n**Timeline/Cost:**\n- **3-5 years, $25-40M** for repurposing tricyclics\n- **6-8 years, $50-80M** for selective CERS modulators\n\n## 6. Complement C1q Subtype Switching\n\n**Druggability: POOR**\n- **C1QA/C1QC**: Secreted proteins, difficult to target selectively\n- **C3AR1**: GPCR, potentially druggable but limited selectivity\n\n**Existing compounds:**\n- **General complement inhibitors**:\n  - **Eculizumab** (Soliris, Alexion, C5 inhibitor, $500K+/year)\n  - **Ravulizumab** (Ultomiris, Alexion, long-acting C5 inhibitor)\n- **C3AR1 antagonists**:\n  - **SB290157** (research tool)\n  - No clinical-stage compounds\n\n**Competitive landscape:**\n- **Alexion/AstraZeneca**: Dominant in complement therapeutics\n- **Achillion/Alexion**: Complement factor D inhibitors\n- **Ra Pharma/UCB**: C5 inhibitors\n\n**Safety concerns:**\n- Complement inhibition increases infection risk (meningococcal)\n- Essential innate immune function\n- C1q subunit selectivity likely impossible\n\n**Timeline/Cost:**\n- **Not viable** - lack of selective targeting tools\n- General complement inhibition: **$200-500K/patient/year**\n\n## 7. Netrin-1 Gradient Restoration\n\n**Druggability: POOR**\n- **NTN1**: Large protein requiring gene/protein therapy\n- **UNC5B/DCC**: Large extracellular domain receptors, poor small molecule targets\n\n**Existing compounds:**\n- **Netrin-1 protein therapy**: No clinical programs\n- **Small molecule netrin modulators**: None exist\n- **Gene therapy**: Theoretical but no programs\n\n**Competitive landscape:**\n- **Spinal Restoration Inc**: Netrin-1 for spinal cord injury (preclinical)\n- No CNS-focused netrin programs for neurodegeneration\n\n**Safety concerns:**\n- Netrin-1 affects axonal guidance and synaptic function\n- Potential developmental pathway reactivation\n- CNS delivery challenges\n\n**Timeline/Cost:**\n- **Not currently viable** - no existing development tools\n- Protein/gene therapy approach: **10+ years, $150-250M**\n\n---\n\n## OVERALL RECOMMENDATION\n\n**Top Priority: Microglial Purinergic Reprogramming (P2RX7 focus)**\n- Established target with clinical compounds\n- Reasonable safety profile from existing trials\n- Clear development path for CNS indications\n- **Immediate next step**: License JNJ-47965567 or similar P2RX7 antagonist for tau studies\n\n**Second Priority: Sphingolipid Metabolism**\n- Repurpose existing tricyclic antidepressants as starting point\n- Well-characterized safety profiles\n- **Immediate next step**: Retrospective analysis of PSP/CBD patients on tricyclics\n\n**Avoid: AQP4, Complement, Netrin-1**\n- Poor druggability or questionable scientific premise\n- No viable development path with current technology\n\n**Research Priority: Glycocalyx and Ephrin**\n- Require more basic research before therapeutic development\n- Potential for future programs if mechanism validated",
  "tokens_used": "1931"
}